Alignment Healthcare (NASDAQ:ALHC) CEO John Kao Sells 82,299 Shares of Stock

Alignment Healthcare, Inc. (NASDAQ:ALHC) CEO John Kao sold 82,299 shares of the stock in a transaction on Monday, April 13th. The shares were sold at an average price of $20.80, for a total value of $1,711,819.20. Following the sale, the chief executive officer directly owned 1,806,641 shares in the company, valued at $37,578,132.80. This trade represents a 4.36% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Alignment Healthcare Trading Up 2.3%

Shares of NASDAQ ALHC opened at $20.98 on Tuesday. Alignment Healthcare, Inc. has a 1-year low of $11.63 and a 1-year high of $23.87. The business has a fifty day moving average price of $19.26 and a 200 day moving average price of $19.07. The stock has a market capitalization of $4.29 billion, a P/E ratio of -2,095.90, a price-to-earnings-growth ratio of 3.00 and a beta of 1.20. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.71 and a quick ratio of 1.71.

Alignment Healthcare (NASDAQ:ALHC) last announced its earnings results on Thursday, February 26th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.10. Alignment Healthcare had a negative net margin of 0.02% and a negative return on equity of 0.49%. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. During the same period in the previous year, the company posted ($0.16) earnings per share. The firm’s revenue was up 44.4% on a year-over-year basis. Equities research analysts expect that Alignment Healthcare, Inc. will post -0.69 EPS for the current fiscal year.

Hedge Funds Weigh In On Alignment Healthcare

A number of institutional investors have recently bought and sold shares of the business. T. Rowe Price Investment Management Inc. boosted its holdings in shares of Alignment Healthcare by 0.6% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 12,643,784 shares of the company’s stock valued at $249,715,000 after acquiring an additional 79,268 shares during the last quarter. Invesco Ltd. lifted its position in Alignment Healthcare by 38.9% during the fourth quarter. Invesco Ltd. now owns 6,202,592 shares of the company’s stock valued at $122,501,000 after purchasing an additional 1,735,962 shares during the period. Mercer Global Advisors Inc. ADV boosted its holdings in Alignment Healthcare by 6.9% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 15,452 shares of the company’s stock valued at $305,000 after purchasing an additional 996 shares during the last quarter. Mackenzie Financial Corp grew its position in Alignment Healthcare by 25.6% during the 4th quarter. Mackenzie Financial Corp now owns 46,917 shares of the company’s stock worth $901,000 after purchasing an additional 9,552 shares during the period. Finally, nVerses Capital LLC purchased a new position in shares of Alignment Healthcare during the 4th quarter valued at about $396,000. 86.19% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have recently weighed in on ALHC. Piper Sandler raised their price objective on Alignment Healthcare from $20.00 to $30.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 6th. KeyCorp reissued an “overweight” rating and issued a $28.00 price target on shares of Alignment Healthcare in a report on Thursday, January 22nd. Robert W. Baird set a $28.00 price objective on shares of Alignment Healthcare in a research report on Friday, January 30th. UBS Group boosted their target price on shares of Alignment Healthcare from $18.00 to $21.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 14th. Finally, Wall Street Zen cut shares of Alignment Healthcare from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $24.75.

About Alignment Healthcare

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.